Literature DB >> 16651401

Lysophosphatidic acid binds to and activates GPR92, a G protein-coupled receptor highly expressed in gastrointestinal lymphocytes.

Knut Kotarsky1, Ake Boketoft, Jesper Bristulf, Niclas E Nilsson, Ake Norberg, Stefan Hansson, Christer Owman, Rannar Sillard, L M Fredrik Leeb-Lundberg, Björn Olde.   

Abstract

Here, the ligand binding, activation, and tissue distribution of the orphan G protein-coupled receptor (GPCR) GPR92 were studied. GPR92 binds and is activated by compounds based on the lysophosphatidic acid (LPA) backbone. The binding of LPA to GPR92 was of high affinity (K(D) = 6.4 +/- 0.9 nM) and led to an increase in both phosphoinositide hydrolysis and cAMP production. GPR92 is atypical in that it has a low sequence homology with the classic LPA(1-3) receptors (21-22%). Expression of GPR92 is mainly found in heart, placenta, spleen, brain, lung, and gut. Notably, GPR92 is highly expressed in the lymphocyte compartment of the gastrointestinal tract. It is the most abundant GPCR activated by LPA found in the small intestinal intraepithelial CD8+ cytotoxic T cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16651401     DOI: 10.1124/jpet.105.098848

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  91 in total

1.  Stimulatory actions of lysophosphatidic acid on mouse ATDC5 chondroprogenitor cells.

Authors:  Ryota Itoh; Shigenori Miura; Aki Takimoto; Shunya Kondo; Hiroko Sano; Yuji Hiraki
Journal:  J Bone Miner Metab       Date:  2010-05-11       Impact factor: 2.626

2.  Lysophosphatidic acid effects on atherosclerosis and thrombosis.

Authors:  Mei-Zhen Cui
Journal:  Clin Lipidol       Date:  2011-08

Review 3.  Gastrointestinal chemosensation: chemosensory cells in the alimentary tract.

Authors:  H Breer; J Eberle; C Frick; D Haid; P Widmayer
Journal:  Histochem Cell Biol       Date:  2012-04-24       Impact factor: 4.304

Review 4.  Regulation of mammalian physiology, development, and disease by the sphingosine 1-phosphate and lysophosphatidic acid receptors.

Authors:  Victoria A Blaho; Timothy Hla
Journal:  Chem Rev       Date:  2011-09-22       Impact factor: 60.622

Review 5.  Insights into the pharmacological relevance of lysophospholipid receptors.

Authors:  Tetsuji Mutoh; Richard Rivera; Jerold Chun
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

Review 6.  International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂.

Authors:  R G Pertwee; A C Howlett; M E Abood; S P H Alexander; V Di Marzo; M R Elphick; P J Greasley; H S Hansen; G Kunos; K Mackie; R Mechoulam; R A Ross
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

Review 7.  International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid receptor nomenclature.

Authors:  Jerold Chun; Timothy Hla; Kevin R Lynch; Sarah Spiegel; Wouter H Moolenaar
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

Review 8.  Pharmacological tools for lysophospholipid GPCRs: development of agonists and antagonists for LPA and S1P receptors.

Authors:  Dong-Soon Im
Journal:  Acta Pharmacol Sin       Date:  2010-08-23       Impact factor: 6.150

Review 9.  Membrane lipid interactions in intestinal ischemia/reperfusion-induced Injury.

Authors:  Emily Archer Slone; Sherry D Fleming
Journal:  Clin Immunol       Date:  2014-05-09       Impact factor: 3.969

Review 10.  Phosphatase-resistant analogues of lysophosphatidic acid: agonists promote healing, antagonists and autotaxin inhibitors treat cancer.

Authors:  Glenn D Prestwich; Joanna Gajewiak; Honglu Zhang; Xiaoyu Xu; Guanghui Yang; Monica Serban
Journal:  Biochim Biophys Acta       Date:  2008-04-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.